Source-grounded facts extracted from PDS Biotechnology Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PDS Biotechnology Corp entered an off-balance-sheet arrangement for guarantee with YA II PN, LTD..
“the Guarantor (together with any other entity that may become a party thereto, the “Guarantors”) and the Investor entered into a Guaranty Agreement (the “Guaranty Agreement”), pursuant to which the Guarantors guaranteed all of the Company’s obligations under the Purchase Agreement and the Promissory Note and related obligations, as more fully described in the Prior 8-K.”
PDS Biotechnology Corp incurred convertible notes of $6,000,000 with YA II PN, LTD. at 10% per annum maturing the twelve-month anniversary of the Closing Date.
“The Promissory Note was issued on the Closing Date with an aggregate face value of $6,000,000 for a purchase price of $5,760,000. The Promissory Note has a maturity date of the twelve-month anniversary of the Closing Date, bears interest at a rate of 10% per annum (subject to increase upon the occurrence and during the continuance of an Event of Default (as defined in the Promissory Note)), and is subject to the redemption, amortization, conversion, beneficial ownership limitation and other provisions described in the Prior 8-K.”
PDS Biotechnology Corp entered into Guaranty Agreement with PDS Operating Corporation and YA II PN, LTD. (effective 2026-06-15).
“In connection with the Purchase Agreement, on the Closing Date, the Guarantor (together with any other entity that may become a party thereto, the “Guarantors”) and the Investor entered into a Guaranty Agreement (the “Guaranty Agreement”), pursuant to which the Guarantors guaranteed all of the Company’s obligations under the Purchase Agreement and the Promissory Note and related obligations, as more fully described in the Prior 8-K.”
PDS Biotechnology Corp entered into Registration Rights Agreement with YA II PN, LTD. (effective 2026-06-15).
“In connection with the Purchase Agreement, on the Closing Date, the Company and the Investor entered into a Registration Rights Agreement (the “Registration Rights Agreement”), pursuant to which the Company is obligated to file a registration statement to register the shares of Common Stock issuable upon conversion of the Promissory Note and exercise of the Warrant within 30 days after the Closing Date, subject to the terms and conditions described in the Prior 8-K.”
PDS Biotechnology Corp entered into Sales Agreement with Yorkville Securities, LLC and B. Riley Securities, Inc. valued at up to $50,000,000 (effective 2026-06-15).
“On the Closing Date, the Company entered into a Sales Agreement (the “Sales Agreement”) with Yorkville Securities, LLC, an affiliate of the Investor (“Yorkville Securities”), and B. Riley Securities, Inc. (“B. Riley Securities,” each of Yorkville Securities and B. Riley Securities individually an “Agent” and collectively, the “Agents”), with respect to an “at-the-market” offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock (the “Placement Shares”) having an aggregate offering price of up to $50,000,000 through or to the Agents, as sales agents or principals.”
PDS Biotechnology Corp reported the quarter ended March 31, 2026 results: net income net loss of approximately $7.3 million, EPS $0.13 per basic and diluted share.
“Reported net loss for the quarter ended March 31, 2026, was approximately $7.3 million, or $0.13 per basic and diluted share”
PDS Biotechnology Corp incurred loan of $6,000,000 with YA II PN, LTD. at 10% per annum maturing twelve-month anniversary of the Closing Date.
“Promissory Note will have an aggregate face value of $6,000,000 and will be issued on the Closing Date for a purchase price of $5,760,000. The Promissory Note will have a maturity date of the twelve-month anniversary of the Closing Date and an interest rate of 10% per annum”
PDS Biotechnology Corp entered into Securities Purchase Agreement with YA II PN, LTD. valued at $6,000,000 (effective 2026-04-30).
“On April 30, 2026 (the “ Effective Date ”), PDS Biotechnology Corporation, a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with YA II PN, LTD.”
PDS Biotechnology Corp reported the year ended December 31, 2025 results: net income approximately $34.5 million, EPS $0.74 per basic and diluted share.
“Full Year 2025 Financial Results Net loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and diluted share for the year ended December 31, 2024.”
PDS Biotechnology Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 25, 2026, PDS Biotechnology Corporation (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s comm”
PDS Biotechnology Corp incurred senior notes of $22,222,222 with JGB Collateral LLC, as Collateral Agent, and the Buyers parties to the Securities Purchase Agreement at prime rate noted in The Wall Street Journal, Money Rates section plus 5% per ann maturing April 20, 2028.
“Pursuant to the Purchase Agreement, the Company agreed to sell to the Buyers (i) Senior Secured Convertible Debentures (the “ Debentures ”) in an aggregate principal amount of $22,222,222 and (ii) warrants to purchase up to 1,000,000 shares of common stock, par value $0.00033 per share (the “ Common Stock ”), for an exercise price of $2.52 per share, which is”
Sir Richard Sykes departed as Director at PDS Biotechnology Corp.
“On April 22, 2025, Sir Richard Sykes, a member of the Board of Directors (the “Board”) of PDS Biotechnology Corporation (the “Company”), notified the Company that he will retire and not stand for re-election as a director of the Company upon the expiration of his current term which expires at the Company’s 2025 Annual Meeting of Stockholders.”
PDS Biotechnology Corp reported the three months ended March 31, 2024 results: net income approximately $10.6 million, EPS $0.30 per basic share and diluted share.
“Reported net loss was approximately $10.6 million, or $0.30 per basic share and diluted share, for the three months ended March 31, 2024”
Stephan F. Toutain was appointed as Chief Operations Officer at PDS Biotechnology Corp.
“PDS Biotechnology Corporation (the “Company”) entered into an Executive Employment Agreement with Stephan F. Toutain (the “Employment Agreement”), pursuant to which Mr. Toutain will assume the role of the Company’s Chief Operations Officer, effective as of May 1, 2024 (the “Effective Date”).”
PDS Biotechnology Corp reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share, EPS $1.39 per basic and diluted share.
“Net loss for the year ended December 31, 2023, was approximately $42.9 million, or $1.39 per basic and diluted share, compared to a net loss of $40.9 million, or $1.43 per basic share and diluted share, for the year ended December 31, 2022.”
Lauren V. Wood retired as Chief Medical Officer at PDS Biotechnology Corp.
“Effective as of January 22, 2024, Lauren V. Wood, M.D. retired from her position as Chief Medical Officer of PDS Biotechnology Corporation (the “Company”).”
Lars Boesgaard was appointed as Chief Financial Officer at PDS Biotechnology Corp.
“On November 28, 2023, the Company entered into an Executive Employment Agreement with Lars Boesgaard (the “ Employment Agreement ”), pursuant to which Mr. Boesgaard will assume the role of the Company’s Chief Financial Officer, effective as of December 4, 2023.”
Matthew Hill resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at PDS Biotechnology Corp.
“On November 21, 2023, Matthew Hill submitted his resignation, effective December 1, 2023, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation (the “ Company ”) in order to pursue other professional endeavors.”
PDS Biotechnology Corp reported financial results for the quarter ended September 30, 2023.
“On November 14, 2023, PDS Biotechnology Corporation (the “Company”) issued a press release announcing its financial results as of and for the three and nine months ended September 30, 2023 and provided an update on the business of the Company.”
PDS Biotechnology Corp reported for the three and six months ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and dilute, EPS ($0.37) per basic share and diluted share.
“Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and diluted share”
PDS Biotechnology Corp shareholders approved Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers.
“The Company’s stockholders voted to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers.”
PDS Biotechnology Corp shareholders approved Ratification of Appointment of KPMG US LLP at the 2023-12-31 meeting.
“The Company’s stockholders ratified the appointment of KPMG US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
PDS Biotechnology Corp shareholders approved Approval of the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.
“The Company’s stockholders voted to approve the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.”
PDS Biotechnology Corp shareholders approved Election of Class B Directors.
“The Company’s stockholders elected the following directors to serve as Class B directors until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.”
PDS Biotechnology Corp reported the three months ended March 31, 2023 results: net income approximately $9.7 million, EPS $0.32 per basic share and diluted share.
“Reported net loss was approximately $9.7 million, or $0.32 per basic share and diluted share, for the three months ended March 31, 2023”
PDS Biotechnology Corp reported the year ended December 31, 2022 results: net income approximately $40.9 million, EPS $1.43 per basic share and diluted share.
“Net loss for the year ended December 31, 2022 was approximately $40.9 million, or $1.43 per basic share and diluted share”
PDS Biotechnology Corp entered into Share Transfer Agreement with Merck KGaA, Darmstadt, Germany valued at aggregate value of $5.0 million (effective 2022-12-30).
“On December 30, 2022, the Company entered into the Share Transfer Agreement with Merck KGaA, Darmstadt, Germany, pursuant to which the Company issued the Shares to Merck KGaA, Darmstadt, Germany in a private placement.”
PDS Biotechnology Corp entered into License Agreement with Merck KGaA, Darmstadt, Germany valued at $5.0 million (effective 2022-12-30).
“On December 30, 2022, PDS Biotechnology Corporation (the “Company”) entered into a License Agreement (the “License Agreement”) with Merck KGaA, Darmstadt, Germany, pursuant to which Merck KGaA, Darmstadt, Germany has granted the Company an exclusive (even as to Merk KGaA), worldwide, sublicensable, milestone and royalty-bearing right and license to certain patent rights and certain related data (the “Licensed Technology”) to develop, manufacture, use, commercialize and otherwise exploit any product containing NHS-IL12 fusion protein known as M9241 (the “Compound”).”
Matthew Hill was appointed as Chief Financial Officer at PDS Biotechnology Corp.
“On October 4, 2021, the Company entered into an Executive Employment Agreement with Matthew Hill (the “ Employment Agreement ”), pursuant to which Mr. Hill will be appointed as the Company’s Chief Financial Officer, effective as of October 18, 2021 (the “ Effective Date ”).”
Janetta Trochimiuk changed role as interim principal accounting officer at PDS Biotechnology Corp.
“Janetta Trochimiuk, the Company’s controller, will serve as the interim principal accounting officer”
Frank Bedu-Addo changed role as interim principal financial officer at PDS Biotechnology Corp.
“Frank Bedu-Addo, the Company’s Chief Executive Officer, will serve as the Company’s interim principal financial officer”
Seth Van Voorhees departed as Chief Financial Officer, principal financial officer and principal accounting officer at PDS Biotechnology Corp.
“On September 30, 2021, PDS Biotechnology Corporation (the “ Company ”) delivered a notice of termination without cause to Seth Van Voorhees and removed him from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.